Structured evidence table for Acetyl-L-Carnitine Fatigue Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Acetyl-L-Carnitine Fatigue Randomized Trial | because of evidence of its use by athletes with the intention of enhancing performance The World Anti-Doping Agency (WADA) classified Meldonium as a prohibited substance effective January 1, 2016. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Acetyl-L-Carnitine Fatigue Randomized Trial | The decision to move Meldonium from the Monitoring program to the Prohibited list was made “…” (WADA 2016 Prohibited List, 16 September 2015), rather than robust scientific evidence demonstrating actual performance enhancement. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Acetyl-L-Carnitine Fatigue Randomized Trial | To date, scientific consensus on Meldonium’s ergogenic effects in humans remains inconclusive, prompting a need for a critical evaluation of the existing evidence hierarchy. | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Acetyl-L-Carnitine Fatigue Randomized Trial | 1 2 β While Western countries commonly refer to substances like Meldonium as “metabolic modulators,” in Eastern countries, they are frequently classified as “antihypoxic agents” (). | 4 | Malm Christer (2026) | Meldonium and human sport performance: a narrative review evaluating the evidence for ergogenic potential |
| Acetyl-L-Carnitine Fatigue Randomized Trial | 1 2 2 3 4 Fibromyalgia (FM) is a disorder of and is frequently associated with other symptoms such as fatigue, sleep disturbances, muscle stiffness, depression, and anxiety [,]. | 4 | do Lago Isabella Oliveira (2026) | Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence |
| Acetyl-L-Carnitine Fatigue Randomized Trial | However, a prominent theory posits reduced or absent inhibitory control in FM compared to healthy individuals, potentially a primary cause of the disorder []. | 4 | do Lago Isabella Oliveira (2026) | Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence |
| Acetyl-L-Carnitine Fatigue Randomized Trial | This review synthesizes 18 recent RCTs (2015–2025), identifying critical evidence gaps including long-term efficacy (>12 months) and combination pharmacological/non-pharmacological approaches. | 4 | do Lago Isabella Oliveira (2026) | Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence |
| Acetyl-L-Carnitine Fatigue Randomized Trial | The prevalence of this syndrome in the global population is between 2% and 4%, predominantly affecting females between the ages of 20 and 55. | 4 | do Lago Isabella Oliveira (2026) | Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence |
Source documents